In late September, the Federal Commerce Fee filed an administrative criticism in opposition to the three largest pharmacy profit managers, alleging that these third-party suppliers had artificially inflated the value of insulin. They did this by intentionally refusing to supply cheaper insulin that was already out there to sufferers due to a “perverse drug low cost program,” based on the […]